Spots Global Cancer Trial Database for renal cell
Every month we try and update this database with for renal cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC | NCT01791387 | Clear Cell Rena... | Dovitinib | 18 Years - | Auckland District Health Board | |
| A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | NCT01946789 | Advanced Solid ... | ALT-803 | 18 Years - | Altor BioScience | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | NCT01946789 | Advanced Solid ... | ALT-803 | 18 Years - | Altor BioScience | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma | NCT01063998 | Renal Cell Carc... | Urine Marker | 18 Years - | William Beaumont Hospitals | |
| Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. | NCT04033991 | Carcinoma Renal Cell | Sunitinib Axitinib | 18 Years - | Pfizer | |
| A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma | NCT00934440 | Renal Cell Carc... | Bevacizumab Azacitidine | 18 Years - | University of Kansas Medical Center | |
| A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma | NCT00934440 | Renal Cell Carc... | Bevacizumab Azacitidine | 18 Years - | University of Kansas Medical Center | |
| A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | NCT01999972 | Advanced Solid ... | axitinib crizotinib axitinib crizotinib axitinib crizotinib | 18 Years - | Pfizer | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | NCT01999972 | Advanced Solid ... | axitinib crizotinib axitinib crizotinib axitinib crizotinib | 18 Years - | Pfizer | |
| Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma | NCT01689766 | Metastatic Rena... | Technetium Tc 9... | 18 Years - | Endocyte | |
| Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma | NCT01689766 | Metastatic Rena... | Technetium Tc 9... | 18 Years - | Endocyte | |
| The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma | NCT00554515 | Metastatic Rena... | HD IL2 | 18 Years - 80 Years | Beth Israel Deaconess Medical Center | |
| Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | NCT00923169 | Renal Cell Carc... | Anti-Transformi... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | NCT04301011 | Solid Tumor Microsatellite ... HPV Positive Or... Cervical Cancer Melanoma (Skin) Cutaneous Squam... Mesothelioma Renal Cell Carc... Oropharynx Canc... | TBio-6517 Pembrolizumab | 18 Years - | Turnstone Biologics, Corp. | |
| Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma | NCT01173445 | Renal Cell Carc... | 18 Years - | University of Kansas Medical Center | ||
| Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | NCT00923169 | Renal Cell Carc... | Anti-Transformi... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma | NCT00934440 | Renal Cell Carc... | Bevacizumab Azacitidine | 18 Years - | University of Kansas Medical Center | |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe | NCT00688753 | Carcinoma Renal Cell Non Clear Cell ... Papillary Cell ... Adenocarcinoma | RAD001 | 18 Years - | Novartis | |
| Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | NCT00609934 | Renal Cell Carc... | Sorafenib external beam r... | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
